Role of perioperative immunotherapy in localized renal cell carcinoma
Jasmeet Kaur1, Goutham Patil2, Daniel M Geynisman1
1Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract:
Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging from 53% to 85% depending on the stage of disease at presentation. Given clinical response to immunotherapies in metastatic RCC, these therapies are being tested as monotherapy and in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors in the (neo)adjuvant setting. Here we describe the current landscape of these treatments in localized RCC.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Tumor Immunotherapy
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
